thinking i will await calimmune interim data in the hope we get a pop out of that, then take the bulk
of my investment out of this Co, leaving just enough in bottom drawer should it ever come good.
i understand biotech slow going etc, but the Co does have form in under delivering so i was watching carefully to see if they are going to hold carrot out further again and it's exactly what they've done.
Now i'm watching for the move where they put this into a nosedive, with the assets sold off cheap to private concern in a fire sale, only for it to miraculously come good later and prove very valuable in a later Pharma deal. TT-033 all over again, except on a much bigger scale. As i said they have form, so we need to be vigilant for it. The chairman might be a lawyer but i don't reckon such a move would go down without a complaint or two from retail holders with long memories.
- Forums
- ASX - By Stock
- BLT
- Ann: Chairman's Address to Shareholders
Ann: Chairman's Address to Shareholders, page-42
-
- There are more pages in this discussion • 26 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BLT (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online